Catherine Rowan

Faith-Based Investor Group Calls for Drugmakers to Be Transparent on Pricing

Members of the Interfaith Center on Corporate Responsibility (ICCR) are asking 17 American drug companies to be more transparent about when and why they raise prices. The investors say rising costs are putting prescription drugs out of reach for many patients. The ICCR hopes the proposals are listed in company proxy statements and put to shareholder votes at annual meetings in spring 2017. Some state legislatures have already introduced bills requiring companies to justify price increases. ICCR member Catherine Rowan hopes they get enough votes to prod companies to adopt pricing-transparency policies. She added that congressional committees have called some pharmaceutical chief executives to testify and the legislative pressures are going to persist.

Syndicate content